Cargando…

Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021

BACKGROUND: Small observational studies have observed poor persistency to sodium-glucose cotransporter-2 inhibitors (SGLT2-i) and glucacon-like-peptide-1-receptor agonists (GLP1-RA), contrary to what has been reported in clinical trials. Therefore, we investigated the risk of discontinuing SGLT2-is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malik, Mariam Elmegaard, Falkentoft, Alexander Christian, Jensen, Jesper, Zahir, Deewa, Parveen, Saaima, Alhakak, Amna, Andersson, Charlotte, Petrie, Mark C., Sattar, Naveed, McMurray, John J.V., Køber, Lars, Schou, Morten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230617/ https://www.ncbi.nlm.nih.gov/pubmed/37265783 http://dx.doi.org/10.1016/j.lanepe.2023.100617

Ejemplares similares

Initiation of Medical Therapy for Heart Failure Patients According to Kidney Function: A Danish Nationwide Study
por: Zahir Anjum, Deewa, et al.
Publicado: (2023)

Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes – a Danish nationwide observational study
por: Falkentoft, Alexander C., et al.
Publicado: (2022)

Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017
por: Arulmurugananthavadivel, Anojhaan, et al.
Publicado: (2021)

Adherence and Discontinuation of Optimal Heart Failure Therapies According to Age: A Danish Nationwide Study
por: Garred, Caroline H., et al.
Publicado: (2022)

Association between early detected heart failure stages and future cardiovascular and non-cardiovascular events in the elderly (Copenhagen Heart Failure Risk Study)
por: Parveen, Saaima, et al.
Publicado: (2022)

Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women
por: Balasubramanian, Akhila, et al.
Publicado: (2013)

Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries
por: Fuller, Douglas S., et al.
Publicado: (2019)

Reinitiation and Subsequent Discontinuation of Antiplatelet Treatment in Nonpersistent Older Patients with Peripheral Arterial Disease
por: Wawruch, Martin, et al.
Publicado: (2021)

Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
por: McGovern, Andrew P, et al.
Publicado: (2020)

Patterns of metformin monotherapy discontinuation and reinitiation in people with type 2 diabetes mellitus in New Zealand
por: Horsburgh, Simon, et al.
Publicado: (2021)

Phosphorylation of a reinitiation supporting protein, RISP, determines its function in translation reinitiation
por: Mancera-Martínez, Eder, et al.
Publicado: (2021)

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study
por: Lugner, Moa, et al.
Publicado: (2021)

Putting a cap on reinitiation
por: LeBrasseur, Nicole
Publicado: (2002)

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
por: Sattar, Naveed, et al.
Publicado: (2016)

Erratum to: SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
por: Sattar, Naveed, et al.
Publicado: (2016)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022)

Auxin Signaling in Regulation of Plant Translation Reinitiation
por: Schepetilnikov, Mikhail, et al.
Publicado: (2017)

Nonsense mutation-dependent reinitiation of translation in mammalian cells
por: Cohen, Sarit, et al.
Publicado: (2019)

Translational coupling via termination-reinitiation in archaea and bacteria
por: Huber, Madeleine, et al.
Publicado: (2019)

Viral strategies of translation initiation: Ribosomal shunt and reinitiation
por: Ryabova, Lyubov A, et al.
Publicado: (2002)

Principles, mechanisms, and biological implications of translation termination–reinitiation
por: Sherlock, Madeline E., et al.
Publicado: (2023)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Pregabalin-associated Discontinuation Symptoms: A Case Report
por: Naveed, Sadiq, et al.
Publicado: (2018)

Comparison of mRNA features affecting translation initiation and reinitiation
por: Osterman, Ilya A., et al.
Publicado: (2013)

Clozapine reinitiation following a “red result” secondary to chemotherapy
por: Munshi, Tariq, et al.
Publicado: (2013)

Ribosome reinitiation at leader peptides increases translation of bacterial proteins
por: Korolev, Semen A., et al.
Publicado: (2016)

Please do not recycle! Translation reinitiation in microbes and higher eukaryotes
por: Gunišová, Stanislava, et al.
Publicado: (2017)

Downstream promoter interactions of TFIID TAFs facilitate transcription reinitiation
por: Joo, Yoo Jin, et al.
Publicado: (2017)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?
por: Wołos-Kłosowicz, Katarzyna, et al.
Publicado: (2022)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

Reinitiation and Subsequent Discontinuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers among New and Prevalent Users Aged 65 Years or More with Peripheral Arterial Disease
por: Wawruch, Martin, et al.
Publicado: (2023)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion
por: Lee, Eun Young, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8o33kgngluetfhnprf5fnrpe1c